Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Tendera

Showing results (101-110 of 131) with videos related to

Pageof 14
Sort By:
The New England Journal of Medicine|March 12, 2013
Treatment of anemia with darbepoetin alfa in systolic heart failureKarl Swedberg, James B Young, Inder S Anand, et al.
European Heart Journal|September 11, 2019
Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registryEmmanuel Sorbets, Kim M Fox, Yedid Elbez, et al.
European Heart Journal|June 7, 2012
From abstract to impact in cardiovascular research: factors predicting publication and citationStephan Winnik, Dimitri A Raptis, Janina H Walker, et al.
Journal of the American College of Cardiology|February 2, 2008
Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularizationPawel E Buszman, Stefan R Kiesz, Andrzej Bochenek, et al.
European Journal of Heart Failure|July 28, 2009
Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trialJohn J V McMurray, Inder S Anand, Rafael Diaz, et al.
Lancet (London, England)|August 31, 2012
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trialBenjamin M Scirica, Marc P Bonaca, Eugene Braunwald, et al.
Journal of the American College of Cardiology|April 16, 2013
Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologicsJozef Bartunek, Atta Behfar, Dariouch Dolatabadi, et al.
International Journal of Cardiology|October 22, 2013
The wealth of nations and the dissemination of cardiovascular researchStephan Winnik, Timo Speer, Dimitri A Raptis, et al.
American Heart Journal|June 23, 2014
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trialRury R Holman, Mary A Bethel, Juliana C N Chan, et al.
European Heart Journal|March 1, 2024
Cardiomyopathies in children and adolescents: aetiology, management, and outcomes in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis RegistryJuan Pablo Kaski, Gabrielle Norrish, Juan Ramon Gimeno Blanes, et al.
Pageof 14

Showing results (101-110 of 131) with videos related to

Sort By:
Pageof 14
The New England Journal of Medicine|March 12, 2013
Treatment of anemia with darbepoetin alfa in systolic heart failureKarl Swedberg, James B Young, Inder S Anand, et al.
European Heart Journal|September 11, 2019
Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registryEmmanuel Sorbets, Kim M Fox, Yedid Elbez, et al.
European Heart Journal|June 7, 2012
From abstract to impact in cardiovascular research: factors predicting publication and citationStephan Winnik, Dimitri A Raptis, Janina H Walker, et al.
Journal of the American College of Cardiology|February 2, 2008
Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularizationPawel E Buszman, Stefan R Kiesz, Andrzej Bochenek, et al.
European Journal of Heart Failure|July 28, 2009
Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trialJohn J V McMurray, Inder S Anand, Rafael Diaz, et al.
Lancet (London, England)|August 31, 2012
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trialBenjamin M Scirica, Marc P Bonaca, Eugene Braunwald, et al.
Journal of the American College of Cardiology|April 16, 2013
Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologicsJozef Bartunek, Atta Behfar, Dariouch Dolatabadi, et al.
International Journal of Cardiology|October 22, 2013
The wealth of nations and the dissemination of cardiovascular researchStephan Winnik, Timo Speer, Dimitri A Raptis, et al.
American Heart Journal|June 23, 2014
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trialRury R Holman, Mary A Bethel, Juliana C N Chan, et al.
European Heart Journal|March 1, 2024
Cardiomyopathies in children and adolescents: aetiology, management, and outcomes in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis RegistryJuan Pablo Kaski, Gabrielle Norrish, Juan Ramon Gimeno Blanes, et al.
Pageof 14